---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268948"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:09:06.153900+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports $14.6M cash; Auxora shows 53% hospital stay reduction in CRSPA cohort

## Summary
- Preliminary cash, equivalents, and short-term investments of $14.6M as of Sept 30, 2023; expected to fund operations through Q3 2024.
- Auxora (zegocractin) reduced average hospital stay from 13.4 to 6.3 days (53% reduction) in initial cohort of CRSPA study vs historical control.
- No patients treated with Auxora required total parenteral nutrition (TPN) vs 68.8% in control.
- Recommended dose established for children with ALL experiencing asparaginase-associated pancreatitis: dose level 1.
- Data to be presented at ASH Meeting Dec 9-12, 2023.

## SEC filing metadata
- accession: 0001193125-23-268948
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523268948/0001193125-23-268948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523268948/d565256d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268948
- JSON: https://secwatch.observer/filing/0001193125-23-268948.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.